Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBio Path Holdings Inc

Bio Path Holdings Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0003 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
104
Market Cap
0.56M

Momentum Score

…

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.05
Low
0.23
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bio-Path Holdings is a clinical-stage biopharmaceutical company developing nucleic-acid therapeutics for oncology using a proprietary delivery platform. Long-term growth may be driven by progression of lead clinical candidates, regulatory approvals, and partnerships, and investors may find the company appealing if its platform produces differentiated safety or efficacy signals and it secures development funding.

Key risks include clinical and regulatory failure of unproven candidates, ongoing funding and dilution needs, and intense oncology competition that could limit commercial prospects.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.26
ROE
-3325.71%
Net Debt
-0.94M
ROCE
-2039.46%
Diluted EPS TTM
-1.14

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -9.89M -16.08M -13.87M -10.44M -10.88M
Net income -9.89M -16.08M -13.84M -10.44M -10.86M
Selling general administrative 4.70M 4.11M 4.74M 4.53M 4.33M
Selling and marketing expenses - 0.12M - - -
Gross profit - -0.18M - - -
Reconciled depreciation 0.16M 0.18M 0.18M 0.16M 0.15M
Ebit - -15.84M -13.90M -10.44M -10.91M
Ebitda - -15.76M -13.72M -10.28M -10.76M
Depreciation and amortization - 0.08M 0.18M 0.16M 0.15M
Non operating income net other - - - - 0.03M
Operating income -11.99M -15.84M -13.90M -10.44M -10.91M
Other operating expenses - 15.84M 13.90M 10.44M 10.91M
Interest expense - - -0.03M 0.00M 0.00M
Interest income 0.01M 0.05M 0.03M 0.00M 0.03M
Net interest income 0.01M 0.05M 0.03M 0.00M 0.03M
Income tax expense - - -0.03M -0.00M -0.03M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 11.99M 15.84M 13.90M 10.44M 10.91M
Cost of revenue - 0.18M - - -
Total other income expense net 2.08M -0.23M 0.03M 0.00M 0.03M
Net income from continuing ops -9.89M -16.67M -13.87M -10.44M -10.88M
Net income applicable to common shares - - - -10.44M -10.88M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 3.88M 3.22M 15.97M 26.57M 16.48M
Other current assets - 1.99M 5.23M 2.37M 2.20M
Total liab 3.73M 2.78M 1.80M 1.11M 1.41M
Total stockholder equity 0.15M 0.44M 14.17M 25.46M 15.07M
Other current liab - 1.35M 0.91M 0.77M 0.97M
Common stock - 0.00M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.00M 0.01M 0.01M 0.01M
Retained earnings -117.50M -107.61M -91.53M -77.66M -67.22M
Other assets - 0.00M - - 0.52M
Cash 1.17M 1.05M 10.38M 23.77M 13.76M
Total current liabilities 3.29M 1.91M 1.68M 0.96M 1.17M
Net debt - -0.94M -10.16M -23.54M -13.43M
Short term debt - 0.10M 0.11M 0.08M 0.09M
Short long term debt total - 0.11M 0.22M 0.23M 0.33M
Other stockholder equity - 108.05M 105.69M 103.11M 82.29M
Property plant equipment - - - 0.43M 0.23M
Total current assets 3.78M 3.04M 15.62M 26.14M 15.96M
Net tangible assets - - - 25.46M 15.07M
Net receivables - 0.00M - - -
Inventory - 0.00M - 0.52M 1.27M
Accounts payable 1.27M 0.46M 0.67M 0.11M 0.10M
Common stock total equity - - - - 0.01M
Retained earnings total equity - - - - -67.22M
Non currrent assets other - 0.08M 0.16M 0.23M 0.29M
Non current assets total 0.11M 0.18M 0.36M 0.43M 0.52M
Capital lease obligations 0.08M 0.11M 0.22M 0.23M 0.33M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - 0.00M -0.02M -0.07M -
Change to liabilities - - - -0.20M -0.08M
Total cashflows from investing activities - - - -0.07M -0.07M
Total cash from financing activities 10.70M 2.20M 1.73M 20.01M 4.29M
Change to operating activities - - - -0.26M -0.72M
Net income -9.89M -16.08M -13.87M -10.44M -10.88M
Change in cash 0.12M -9.33M -13.39M 10.02M -6.67M
Begin period cash flow 1.05M 10.38M 23.77M 13.76M 20.43M
End period cash flow 1.17M 1.05M 10.38M 23.77M 13.76M
Total cash from operating activities -10.57M -11.54M -15.10M -9.92M -10.96M
Issuance of capital stock 10.70M 3.42M 1.73M 15.85M 4.29M
Depreciation 0.16M 0.18M 0.18M 0.16M 0.15M
Sale purchase of stock - - - - 4.29M
Other cashflows from financing activities - 0.53M -0.02M 4.16M -
Change to netincome - - - 0.82M 0.58M
Capital expenditures 0.00M 0.00M 0.02M 0.07M 0.07M
Cash flows other operating - - - - -0.64M
Cash and cash equivalents changes - - - - -6.67M
Change in working capital 0.68M 3.13M -2.26M -0.46M -0.81M
Stock based compensation 0.57M 0.73M 0.85M 0.82M 0.58M
Other non cash items - 0.50M - 10.90M 5.15M
Free cash flow -10.57M -11.54M -15.12M -9.99M -10.96M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BPTH
Bio Path Holdings Inc		 -
-%		 0.00 - 84.75 39.57 1.90 61.75 0.03
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Bio Path Holdings Inc

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

4710 Bellaire Boulevard, Bellaire, TX, United States, 77401

832 742 1357

https://www.biopathholdings.com

1

Name Title Year Born
Mr. Peter H. Nielsen MBA Co-Founder, Chairman, CEO, Pres, CFO & Treasurer 1949
Mr. Douglas P. Morris Co-Founder, Director of Investor Relations, Sec. & Director 1956
Mr. Anthony Price Sr. VP of Fin., Accounting & Admin. NA
Dr. Ana Tari Ashizawa Ph.D., MBA Sr. VP of Research, Devel. & Clinical Design NA
Dr. Alan MacKenzie Ph.D. Consultant NA
Dr. Thomas A. Walker Ph.D. Consultant NA
Dr. Jeffery Lancet M.D. Consultant NA
Ms. Victoria Lake Rac Regulatory Consultant NA
Mr. Peter H. Nielsen MBA Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer 1949
Mr. Douglas P. Morris Co-Founder, Director of Investor Relations, Secretary & Director 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…